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Malaria, the disease caused by Plasmodium sp., claims the lives of over 1 million people 
every year, with Plasmodium falciparum causing the highest morbidity.  Rapidly acquiring drug 
resistance is threatening to exhaust our antimalarial drug arsenal and already requires the 
utilization of combination drug therapy in most cases.  The global need for novel antimalarial 
chemical scaffolds has never been greater. 
Screening of natural product libraries is known to have higher hit rates than synthetic 
chemical libraries.  This elevated hit rate is somewhat attributed to the greater biodiversity 
available in natural products.  Marine life is the most biodiverse system on the planet, containing 
34 of the 36 known phyla of life, and is expected to be a rich source of novel chemotypes.   In 
collaboration with the Harbor Branch Oceanographic Institute in Ft. Pierce we have screened a 
library of over 2,800 marine macroorganism peak fractions against Plasmodium falciparum 
using the SYBR green I fluorescence-based assay.  In this screening process we have identified 
six compounds from five novel chemical scaffolds all of which have low micromolar to 
submicromolar IC50 values and excellent selectivity indices.  Additionally, one of these chemical 
scaffolds, the bis(indolyl)imidazole, was selected for further in vitro pharmacological and 
structure-activity relationship (SAR) profiling, key steps in the challenging process of identifying 
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CHAPTER ONE: INTRODUCTION 
Malaria Background 
Malaria, a term from the Latin words ‘mal’ ‘aria’ meaning ‘bad air’, is caused by the 
parasite genus Plasmodium of the apicomplexan family. Once infected the most common 
symptoms include fever, headache, malaise, myalgias, arthralgia, low back pain, nausea, 
vomiting, diarrhea and cough [1]. The most prevalent human parasites are Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria, and Plasmodium 
knowlesi, with Plasmodium falciparum causing the highest global mortality [2].  Despite the fact 
that Malaria has been a major cause of mortality and morbidity for thousands of years [3], recent 
estimates conclude that around 3.3 billion people are still at risk of contracting malaria, and over 
1,000,000 people die annually from the disease [2].  Over 85% of the mortality occurs in 
children under 5 years old. 
Plasmodium falciparum Life Cycle 
The Plasmodium falciparum life cycle involves two separate hosts, the female Anopheles 
mosquito and the human.  The parasite enters the mosquito during a blood meal as exflagellated 
motile microgametes and macrogametes [4].  These quickly form male and female gametocytes 
which undergo gametogenesis to form ookinetes.  The ookinetes then migrate to the mid-gut 
epithelium basal lamina [5], where the ookinetes develop into oocytes and mature into 
sporozoites that rupture through the basal lamina and migrate to the mosquito salivary gland [6].  
Upon the mosquito’s next blood meal, sporozoites travel from the mosquito salivary gland and 
into the human blood stream.  Within 30 seconds to two minutes the sporozoites must travel 
along the human blood stream and terminally lodge within hepatocyte cells where they will 
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replicate to over 10,000 merozoites in a process called schizogony [7, 8].  Eventually, a 
merosome, full of hundreds of merozoites, will bud and release the merozoites inside the blood 
stream, each of which will infect a red blood cell [9]. Over the next 48 hours the intra-
erythrocytic merozoite will develop into a ring, then a trophozoite, followed by schizont.  Within 
the schizont stage the parasite undergoes many consecutive cycles of replication forming a 10-20 
nucleated merozoites in what is called a segmenter stage.  After entering segmenter stage the 
parasites will egress from the red blood cell as many new merozoites, which struggle to find and 
invade nearby red blood cells and begin the intra-erythrocytic process again.  Upon release of the 
merozoites from the red blood cell, tumor necrosis factor and other cytokines are also released 
which explain the cyclical symptomology [9]. 
This asexual life cycle is broken approximately 1% of the time when a ring will form a 
microgametes or a macrogametes [9].  These sexual stages can be brought into the mosquito 
during a blood meal and will develop as mentioned above.  The complete Plasmodium spp. life 








Current Treatment and Prevention Strategies 
Per the World Health Organization (WHO) “Malaria is an entirely preventable and treatable 
disease, provided that currently recommended interventions are properly implemented” [2] 
Prevention 
 “The goals of malaria vector control are two-fold: 
1) To protect individual people against infective malaria mosquito bites 
2) To reduce the intensity of local malaria transmission at community level by reducing 
the longevity, density and human-vector contact of the local vector mosquito 
population” [2] 
Insecticide Treated Bed Nets- 
The best preventative measure for malaria is utilizing insecticide treated bed nets (ITN’s).  
These nets, originally tested in the 1990’s, showed a remarkable reduction in child mortality of 
over 20% [10]! As early as 1898, the recognition that mosquito nets could reduce the parasite 
load was being taught by Sir Ronald Ross [11].   The practice of saturating the bed nets in 
pyrethroids shows similar decreases in child mortality and also shows some proximity protection 
as well [12].  These long-lasting insecticide treated nets (LLIN) significantly decreased the 
parasite load and the WHO recommended ceasing distributing a set number per household and 
start distributing these nets universally as the protection is far greater under a net than it is by 
proximity only [13]. Also, historically 96% of those who have a bed net will use it, suggesting 
that this could be a great preventative measure [2]. 
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Indoor Residual Spraying- 
 A second line of defense is indoor residual spraying (IRS) of insecticides, preferably 
long-lasting insecticides.  This method requires multiple rounds of spraying each year and can be 
somewhat costly, especially for very-low income countries [14].  Remarkably, 2010 showed an 
increase in IRS usage with over 70% of countries using long-lasting pyrethroids.  Although 
many countries in Africa reported decreased usage of IRS, the western world (specifically China) 
more than compensated to bring the increased total above what was done previously.  The 
dominating use of pyrethroids for both ITN’s and in IRS promotes concern for possible vector 
resistance [2].  IRS can be from any of the other three insecticide classes: organochlorine (DDT), 
organophosphate, or carbamate; whereas pyrethroids are the only ITN approved chemical class 
at this time.  Understandably, cost could be an issue, DDT is roughly the same price as the 
relatively inexpensive pyrethroids, but organophosphates and carbamates can be as much as 4 
times the price of pyrethroids [2].  Overall, of the reporting countries, 11% of at risk populations 
are currently protected by IRS which, although increasing each year, still needs great 
improvement, and it is clear that for a global increase in IRS use and availability, funding will 
need to be increased. 
 
Vaccination- 
A third preventative option, an ideal one, could include vaccination against malaria.  
Since 1910 development of a malaria vaccine has escaped the reach of the scientific community, 
although many great strides have been taken.  Most recently GlaxoSmithKline developed the 
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RTS,S vaccine which combines circumsporozoite protein antibodies with a hepatitis B vector 
and the AS01 immune response boosting adjuvant.  This vaccine, also known as Mosquirix, is 
currently undergoing phase III clinical trials.   Preliminary findings suggest a decrease in 
mortality by 50% in infants and children.  These findings however, are yet to be verified [15].  If 
successful, this could be the first malaria vaccine, although improvement is still needed to 
increase efficacy beyond 50%.   
Garcia-Basterio et al.[15] recommend that in order for a vaccine to be effective in 
preventing malaria it is desirable that it has the following qualities: 
-“Be effective preventing clinical disease, severe malaria and transmission in the  
community 
-Be completely safe for young infants and risk populations (pregnant women, people with 
immune deficiencies or other co-morbidities), with a similar safety profile as other EPI 
vaccines 
-Provide protection against the 5 species of malaria plasmodia 
-Provide long-lasting immunity 
-Be administrable in the first months of life 
-Single oral - dose regime compatible with vaccines of the expanded program on  
immunization (EPI) 
-Easily manufactured, deployed, stored and handled 
-Affordable for governments of low income countries 
-Stable at room temperature 




 Currently there are over seven chemical classes used in the treatment of Plasmodium spp. 
infections including: antifolates, endoperoxides, 4- and 8- aminoquinolines, sulfonamides, amino 
alcohols, and antibiotics.  Of these, the most common currently used chemical classes 
(aminoquinolines, endoperoxides, and antifolates- including sulfonamides) will be discussed in 
more detail. 
 It is important to note that the WHO recommends any treatment of malaria should 
include combination therapy.  As each chemical class has a different mode of action it is 
believed that the growing trend of drug resistant parasites can be curtailed if combinations of 
chemicals which inhibit different targets, as well as different stages of life cycle development are 
used in conjunction.  A brief structural representation of the different antimalarial drug classes 








4- and 8- Aminoquinolines 
 
Figure 3- 4- and 8- Aminoquinolines 
 
For almost 400 years aminoquinolines, like those in figure 3, have been used to treat 
malaria.  Isolated from Cinchona tree bark in the Andes mountain range, quinine use was taught 
by the native South and Central American people to Spanish Jesuits in the early 1600’s [17].  
Because of the limited cultivation and expense of quinine, it became apparent that direct 
chemical synthesis was needed.  Quinine derivatives were successfully synthesized as early as 
the 1920’s and one particular derivative of note, Resochin, was synthesized in 1934 by Hans 
Andersag.  Unfortunately, Resochin was determined to be slightly more toxic than the previous 
quinine derivative in use: Plasmochin, and the clinical study of Resochin ended prematurely 
[18]. Nearly a decade later, under the US Board for the Coordination of Malarial Studies, 
Resochin was rediscovered as the substance SN-7619, and was named Chloroquine though it was 
structurally the identical of Resochin [18]. 
By the 1960’s, Chloroquine became one of the most widely sold of all medications and 
its ability to serve as both a prophylactic and a preventative treatment only increased its 
antimalarial value [7].  Chloroquine destroys the parasite by entering into the parasite digestive 
vacuole and binding hematin (a toxic by-product of hemoglobin digestion by the parasite.).  
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Normally, the hematin is polymerized into an inert hemozoin crystal.  This detoxification is 
disrupted by chloroquine and the build-up of toxic hematin destroys the parasite [19]. 
In 1955 the WHO began the Malaria Eradication Program utilizing chloroquine as the 
sole treatment for infected humans, and the insecticide DDT to tackle the vector control [8]. 
Using these resources, the WHO successfully eradicated malaria from 24 countries by 1982.  
Unfortunately, the nations where malaria was not eradicated soon were dominated by a rapid 
wave of chloroquine resistant Plasmodium falciparum [20].  
These resistant strains of P. falciparum were shown to have mutations in key transport 
proteins which allowed the parasite to decrease chloroquine concentrations in the digestive 
vacuole.  This transport protein is called Plasmodium falciparum chloroquine resistant 
transporter protein (pfcrt).  Because of the decreased efficacy of chloroquine, many nations 
discontinued its use and switched to antifolate combination therapy.  Interestingly, after 8 years 
of discontinued chloroquine use to treat malaria in Malawi, a test group of 210 patients treated 
with chloroquine showed that chloroquine sensitivity was restored and that the use of 
chloroquine was much more effective at reducing host parasitemia than the antifolate 
combination therapy [21].  Similar studies in other nations also showed increased chloroquine 
efficacy after discontinued use for some period of time.  This lends credibility to the idea that if a 
chemical treatment is shown to have resistance, it must be temporarily discontinued for some 
time and then it may be brought back into use.  The principle concept behind this is the belief 
that the mechanism of resistance will be lost from the parasite over time. Jensen et al. describe 
this practice as “drug cycling”.  How effective this method will be over time, and whether or not 
this method can be applied to other antimalarial drugs remains to be seen [7]. 
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Antifolates and Sulfonamides 
 Because of a rise in chloroquine resistant parasites, another chemical class of 
antimalarials needed to be developed.  This new chemical class was antifolates.  Antifolates 
inhibit the production of tetrahydrofolate, a necessary step in DNA, RNA, and protein 
metabolism.  Two signature targets of antifolates in Plasmodium spp. include inhibition of 
dihydropteroate synthase (DHPS) by sulfonamides and inhibition of dihydrofolate reducatase 
(DHFR) by pyrimethamine or cycloguanil. (Figure 4).   
DHPS catalyzes the production of 7,8 dihydropteroate from 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate and p-Aminobenzoic acid (pABA)[22].  It is clear that 
sulfonamides, like sulfadoxine, bind to DHPS and, due to structural similarities, inhibit pABA 
from interacting [23].  This is antagonistically reversible inhibition, as increasing pABA 
concentrations in the media has been shown to decreases sulfadoxine activity [24].   
In addition to sulfonamide mediated DHPS inhibition, another class of antifolates, 
pyrimethamine, cycloguanil, etc., inhibit dihydrofolate reductase (DHFR).  These chemicals 
have a strong structural resemblance to dihydrofolic acid (the natural substrate of DHFR) and are 
able to bind to DHFR and inhibit tetrahydrofolate production [25]. One of the major reasons that 
antifolates, like pyrimethamine, are so advantageous in the treatment of malaria is the fact that 
protozoan DHFR has a much greater affinity for these inhibitors than human DHFR [26].   
Unfortunately, within a short number of years of acceptance as an antimalarial treatment, 
cases of antifolate drug resistant Plasmodium strains surfaced [27].  Most methods of resistance 
include DHFR or DHPS gene point mutations [28, 29]. which significantly decrease the binding 
affinity for the drug(s).  These mutations could have arisen from the many years of sulfadoxine 
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and pyrimethamine combination therapy that replaced chloroquine treatment throughout Africa.  
Although inexpensive and valued for its single dose treatment, the slow excretion of these drugs 
from the body could also have facilitated resistance development [3].    
 
 
Figure 4- Folate Biosynthesis (http://priweb.cc.huji.ac.il/malaria//maps/folatebiopath.html) 
 
Endoperoxides 
 Endoperoxides are derived from the parent compound artemisinin (Figure 5).  
Artemisinin, or qinghaosu, is a natural compound from the plant Artemisia annua.  Lacking the 
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typical nitrogen-substituted rings, the sesquiterpene lactone artemisinin has a peroxide bridge 
making it very unique among antimalarial drug classes [30].  Although the mechanism of action 
is still unknown, it is believed that within the digestive vacuole the peroxide reacts with the heme 
to produce free radicals [31] which can lead to the disruption of lipid membranes [32] and the 
alkylation of specific intracellular targets (heme or other proteins like metalloporphyrins [33]).   
One of the great benefits of Artemisinin is a rapid treatment response backed with a short 
half-life [34].  Most cases of infection can be eliminated completely after the first 48 hours of 
artemisinin treatment [35].  This swift action also provides successful treatment of potentially 
fatal cerebral malaria [36].  Unfortunately, the speed of action, like a two edged sword, has been 
cited in studies as a potential for developing drug resistance, as many patients after the first dose 
would begin to feel better and would stop treatment before total parasite elimination was 
completed [37, 38].  In fact, artemisinin treatment failures have already been announced in a few 
isolated instances.  Most of these cases are from regions known to cultivate multi-drug resistant 
strains and many question if the failure was truly from growing resistance or from the patient’s 
medication non-compliance.  In any case, this unusual delay in the parasite development of drug 
resistance could arise in part from artemisinin’s very short half-life as discussed above which 
could prevent adaptive resistance typically formed in lingering sub-therapeutic drug level 
environments.  Another cause for delayed artemisinin resistance could be the early decision to 
use artemisinin drugs in combination therapies (ACT’s) with longer acting drugs [3].  Numerous 
studies show that ACT treatment results in decreased rates of recrudescence and cases of latent 









Malaria Therapeutics Development 
 The ever increasing rate of drug resistance has awakened a renewed effort in drug 
discovery over the past decade.  In fact most current treatment options show some degree of 
resistance or exhibit the classical signs of the emergence of resistance (Table 1) 
Table 1- Existing Antimalarial Drugs and Their Use [40] 







combination therapies (ACTs) 
Possibly emerging 
Lumefantrine Arylamino alcohol 
Most common first-line 
antimalarial therapy in Africa, 
in combination with artemether 




In combination with artesunate 





In combination with 
dihydroartemisinin in parts of 
southeast Asia 




In combination with artesunate 






Being registered for combined 






Mainly for treating severe 
malaria, often with antibiotics 
Exists at a low 
level 
Atovaquone Naphthoquinone 
In combination with proguanil 
(a biguanide) for treatment or 
prevention 
Has been observed 
clinically 
Chloroquine 4-Aminoquinoline 




For intermittent preventive 
treatment, combined with 
sulphadoxine (a sulphonamide) 
Widespread 
Primaquine 8-Aminoquinoline 
For eliminating liver-stage 
parasites, including dormant 




The ability to find new antimalarial drugs requires collaborations between pharmaceutical 
companies, academia and government agencies for any hope of a speedy resolution.  Two such 
collaborations, Guiguemde et al. and Gamo et al., submitted their work in 2010 and showed how 
partnerships can be used to resupply our antimalarial pipeline [41, 42].  Both studies used high-
throughput screening of vast chemical libraries to find new chemical classes that demonstrate 
antimalarial activity.  Medicines for Malaria Venture (MMV) is a drug discovery hub where 
pharmaceuticals, academia and government funding compile data and collaborate to find the cure 
for malaria.  Unfortunately, even with this collaborative support effort, finding novel antimalarial 
candidates is proving to be very difficult.  The current antimalarial pipeline is shown in Table 2.  
In order for the pipeline to maintain continuous flow, new leads must frequently be identified.  
One of the most common methods of lead generation is through screening of synthetic 
compound or natural product libraries. Once leads are identified, medicinal chemistry can begin 
with lead optimization.  The lead will cycle multiple times between screening and optimizing 
until the best possible pre-clinical candidate is generated. 
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Table 2- MMV Antimalarial Pipeline  
(http://www.mmv.org/research-development/rd-portfolio.) [43] 
 
Compounds from synthetic libraries have known chemical synthetic schemes and 
possibly some understanding of mechanism of action from previous screening in other systems.  
In contrast, natural product libraries are typically extracts containing up to hundreds of 
compounds which can be screened for activity against various targets/organisms.  If the extract 
shows some activity it will be sent for dereplication, a process that isolates the compounds from 
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one another within an extract.  In either case, synthetic or natural, once a compound is identified 
as the source of activity, cytotoxic analysis is done to rule out any early cytotoxic concerns and 
to develop a therapeutic window called the selectivity index.  It is also common to run an ADME 
(Absorption, Distribution, Metabolism, and Excretion) profile on the early lead compound to 
determine any preliminary pharmacodynamics or pharmacokinetic pitfalls. Following this front-
end intensive pattern for drug lead discovery will save millions of dollars and significantly speed 
up drug approval processing once the drug candidate is found. 
 
Marine Natural Products 
 With the oceans covering over 70% of the world and 34 of the 36 known phyla of life 
contained therein, marine life presents itself as a relatively untapped reservoir for novel 
chemotherapeutics.  In the 1950's the first bioactive marine chemicals spongothymidine and 
spongouridine were purified from the Tethya crypta sponge [44].  Since those initial discoveries, 
over 15,000 novel and bioactive marine natural products have been isolated [45] and many have 
shown to have excellent anti-inflammatory, antifungal, anti-infective, antimicrobial, anticancer, 
antituberculosis, and antiprotozoal activity.  A few examples of bioactive marine natural 
products and their targets are listed in table 3.  Many of these marine natural products (MNPs) 
have gone on to clinical trials and many others are still in early development. 
In 1992, the sesquiterpenes chemical class was isolated from the Australian sponge 
Acanthella klethra and was shown to have antimalarial activity [46].  Over the following 20 
years many different chemical classes showing potent antimalarial activity have been identified 
from marine life; Including sponges, marine bacteria, and colonial ascidians [47]. 
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Table 3- Selection of marine compounds with potent and varied activities.[48] 
Drug Class Compound Organism Chemistry IC50 
Antibacterial Ascochytatin Fungus Polyketide 0.3µg 
Antibacterial 





Antibacterial Arenicin-1 Polychaete Peptide 2µg/mL 
Antibacterial Isoaaptamine Sponge Alkaloid 3.7µg/mL 
Antibacterial Sesterterpenes Sponge Terpenoid 
1.56-
12.5µg/mL 
Anticoagulant Anticoagulant pepetide Bivalve Protein 77.9nM 




Antifungal Neopeltolide Sponge Polyketide 0.62µg/mL 
Antiprotozoal Plakortide Sponge Polyketide 
0.5-
2.3µg/mL 
Antiprotozoal Viridamides A & B Bacterium Peptide 1.1-1.5µM 
Antiprotozoal Chaetoxanthone B Fungus Polyketide 1.5µg/mL 





21.5 & 43.0 
µM 









Alga Polysaccharide 0.8-16µg/mL 
Antiviral 6,6'-Bieckol Alga Skikimate 1.07-1.72 µM 





CHAPTER TWO: MATERIALS AND METHODS 
Culturing P. falciparum  
 P. falciparum Dd2 and 3D7 strains were cultured using a modified Trager and Jensen 
method [49] in RPMI media with L-glutamine (Invitrogen) and supplemented with 25mM 
HEPES, 26 mM NaHCO3, 2% dextrose, 15mg/L hypoxanthine, 25mg/L gentamycin,  and 0.5% 
Albumax I.  Culture media was changed daily and incubated at 37°C in 5% CO2 and 95% air. 
The 3D7 strain is a chloroquine sensitive strain characterized as chloroquine sensitive, 
pyrimethamine sensitive, mefloquine sensitive, and artemisisin sensitive.  The Dd2 strain was 
used as a chloroquine resistant strain with resistance to chloroquine, pyrimethamine, and 
mefloquine but sensitivitity to artemisinin. A blood smear was done daily and a Giemsa stain 
was used to determine parasitemia.  When parasitemia reached 10-15%, the culture was split 
down and resupplied with washed and 50% diluted A+ blood received from the Central Florida 
Blood Bank. 
 
SYBR Green-I Fluorescence Assay   
 In comparing antimalarial screening assays it is clear that SYBR Green I is both less 
expensive than PICOGREEN and [H
3
]-hypoxanthine incorporation assays and also produces the 
lowest signal to noise ratio of the three assays in screening of natural product extracts [50] Given 
these two advantages, SYBR Green I was selected as our means of determining antimalarial 
activity.  Because the Plasmodium falciparum host is the RBC which has no DNA, and since 
SYBR Green is a known DNA intercalating agent which will emit excitation induced light only 
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after binding to DNA, this assay can be used to quantify DNA levels and therefore, to quantify 
inhibition levels. 
Different dilutions of the compound/fraction in 1 µl of the culture medium were added to 
99 µl of P. falciparum culture at a 1% parasitemia and 2% hematocrit in 96-well plates. 
Maximum DMSO concentration in the culture never exceeded 0.125%. Chloroquine at 1 µM 
was used as a positive control to determine the baseline value. Following 72 hours incubation at 
37ºC, the plates were frozen at -80ºC. After thawing the plates at room temperature 100 µl of 
lysis buffer (with 20mM Tris-HCL, 0.08% Saponin, 5mM EDTA, 0.8%Triton X-100, and 0.01% 
SYBR Green I) was added to each well. Plates were incubated in the dark for 30 minutes at 37ºC 
followed by fluorescence emission reading using a Synergy H4 hybrid multimode plate reader 
(Biotek) set at 485nm excitation and 530nm emission.   
 
Fibroblast Cytotoxicity Assay  
 Compounds were evaluated for cytotoxicity using NIH/3T3 fibroblast cells. A 384 well 
plate was seeded with 2,500 cells/well (total volume 50µL) and incubated for 24 hours.  Serial 
dilutions of the compound were added to the plate and plates were incubated for an additional 48 
hours. Fifty µL MTS  [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), CellTiter 96® Aqueous non-radioactive cell proliferation assay, 
Promega] reagent was added to each well and the plates were incubated for an additional 3 
hours.  Cell viability was obtained by measuring the absorbance at 490nm using Synergy H4 




Sensitivity and Reliability Statistical Analysis 
 In order to validate active hits and recognize and quantify sensitivity and accuracy of 
each assay we utilized a Z-factor analysis.  This assay was originally developed by Zhang et al 
[51], for HTS validation. The equation is shown below. The Z-factor is a range from 0 to 1.  The 
closer the score is to the value of 1, the more ideal are the assay conditions and the more valid 
are the hit results.  A value below 0.5 is considered unreliable and perhaps requires some 
modifications before the assay can be re-run.  A value between 0.5 and 1 is considered 
acceptable for hit validation  
            (
(     )
(      )
) 
 
 Where σp represents the standard deviation of the positive controls and σn is the standard 
deviation of negative controls.  Also, µp represents the mean of the positive controls and µn 




CHAPTER THREE: IDENTIFICATION OF NOVEL ANTIMALARIALS FROM 
MARINE NATURAL PRODUCTS 
Primary Screening of HBOI Peak Fractions 
 The Harbor Branch Oceanographic Institute in Fort Pierce, Florida began marine natural 
product drug discovery in 1984.  The HBOI collection program has two specific aims: to 
maximize taxonomic diversity; and to evaluate how ecological factors relate to secondary 
metabolite expression.  Dedication to these two primary aims has already resulted in the 
publication of over 100 bioactive marine natural products and over 96 patents to protect these 
discoveries.  Their vast library includes many uncommon marine organisms, primarily collected 
by the Johnson Sea-Link submersible, which is capable of collecting samples at depths of almost 
1000m, an order of magnitude deeper than typical scuba-access derived collection (<100m).   
Given the proximity of HBOI and their unique collection of marine life fractions we 
began a collaborative effort to screen over 2,600 marine natural product peak fractions in search 
of novel antimalarial chemical scaffolds.  This joint UCF-HBOI drug development scheme is 




Figure 6-UCF-HBOI Drug Development Scheme 
 
 In the screening process we quickly identified two-hundred fifty-three active fractions 
against the chloroquine sensitive Plasmodium 3D7 strain.  Any fraction which demonstrated 
greater than 70% inhibition of parasite at a concentration of 5µg/ml was defined as an active 
fraction.  A list of macroorganims sources for these fractions can be found in table 4. 
 
Table 4 Macroorganism Sources of Active Peak Fractions 
 
 
 The active fractions were next prioritized by selecting the top 2 active fractions per 
species.  This resulted in 31 active fractions which were then screened against the 3d7 parasite 
Coral Sponge Mollusk Other
Number of Different 
Species with Active 
Fractions
3 13 1 3
                                                                        Active Peak Fraction Origins                                                                           
(active = >70% inhibition @ 5μ/ml)
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strain at different concentrations to determine the IC50.  Table 5 represents the result of this 
screening process.  These results were sent back to HBOI where the fractions were further 
purified and dereplicated. 
Table 5 Antimalarial Activity of HBOI Peak Fractions 
 
All data are the mean of at least three independent experiments. 
 
Primary Screening of HBOI Purified Fractions 
 As the prioritized active fractions were purified and dereplicated, they were fractionated 
out and sent back to UCF for additional screening.  Over 200 purified fractions were received 
from HBOI in two separate shipments. The purified fractions from the first shipment were 










12.A09 0.73 18.F01 0.98 30.A01 0.99
13.H07 1.1 18.G07 0.44 31.C08 1.1
16.A01 0.67 22.A01 0.82 32.C02 0.08
18.A01 0.62 23.F01 1.1 33.A03 1.2
18.A10 0.52 24.C05 0.21 39.A05 0.75
18.C05 0.23 27.B10 0.51 39.A06 0.6
18.D08 0.73 27.C10 0.47 39.A10 0.85
18.EO3 0.96 29.A07 0.52
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Table 6- Purified fractions antiplasmodial IC50 
Fraction Field ID Dd2 IC
50





4.B07 Aplysina sp. 1.20 18.D08 Paramuriceidae 0.73 
7.G05 Peysonellia 1.30 18.EO3 Paragorgai 0.96 
7.G11 Peysonellia 1.00 18.F01 Spongosorites 0.34 
9.G07 Axinellida? 0.80 18.G03 Paramuriceidae Unid. sp. 0.83 
10.C11 Spirastrella sp. 0.90 18.G07 Paramuricea sp. 0.44 
10.D08 Gastropoda, Aplysia? sp. 0.10 22.A01 Dendroceratida 0.82 
10.D09 Gastropoda, Aplysia? sp. 0.50 23.F01 Erylus sp. 1.12 
11.A08 Gorgonacea 1.20 24.C05 Pachastrellidae 0.46 
11.H01 Axinellida 1.20 27.C10 Amphibleptula 0.47 
11.H02 Axinellida 1.20 29.A07 Axinellidae 1.24 
12.A09 Axinellida 0.74 30.A01 Spongiidae 0.99 
12.A10 Axinellida 0.26 30.B11 Spongiidae 1.43 
13.H07 Leiodermatium? sp. 1.13 31.B11 Choristida 1.40 
15.D04 Xestospongia? sp. 1.58 31.C08 Choristida 1.17 
15.D07 Xestospongia? sp. 1.30 32.C02 Halichondriidae 1.20 
15.H06 Halichondrida? 1.25 33.A03 Spongiidae 1.20 
18.A01 Poecillastra 1.93 39.A05 Aplysina 0.75 
18.A10 Plexauridae 1.44 39.A06 Aplysina 0.60 
18.C04 Myrmekioderma styx 0.65 39.A10 Aplysina 0.85 
All data are the mean of at least three independent experiments. 
 
All fractions with an IC50 at or below 1µg/mL were further screened for cytotoxicity.  
Unfortunately, several of these fractions were depleted prior to cytotoxicity screening and were 
hence removed from further analysis at this time.  The resulting selectivity indices are shown in 
table 7 and further dereplication of a few of these fractions was included in the second shipment 




Table 7- Selectivity indices of all fractions with <1µg/mL IC50 in Dd2 











7.G11 Peysonellia 1.00 47 47 
9.G07 Axinellida? 0.80 33 41 
10.C11 Spirastrella sp. 0.90 48 53 
10.D08 Gastropoda, aplysia? sp. 0.10 31 310 
10.D09 Gastropoda, aplysia? sp. 0.50 29 59 
18.D08 Paramuriceidae 0.73 >50 >68 
18.EO3 Paragorgai 0.96 >50 >52 
18.G07 Paramuricea sp. 0.44 >50 >113 
27.C10 Amphibleptula 0.47 >50 >105 
39.A05 Aplysina 0.75 >50 >67 
39.A06 Aplysina 0.60 >50 >83 
39.A10 Aplysina 0.85 >50 >59 
All data are the mean of at least three independent experiments. 
 
The second shipment of purified fractions also contained several active purified fractions 
from 7 distinct species which all showed to have antiplasmodial activity in the initial screening 
tests.   Among this shipment were the purified fractions from species which had multiple active 
fractions in the initial screening, including: Choristida sp., Bebryce sp., Amphibleptula sp., 
Aplysina sp., and Auletta sp. derive fractions.  The top fraction from each organism is listed in 
table 8.  These results have been sent back to HBOI and further dereplication and purified 





Table 8- Potent antimalarial HBOI purified fractions 
Organism ID Genus IC50 (µg/mL) 
10-V-00-1-004 Bebryce sp. 0.47 
31-III-89-2-003 Amphibleptula sp. 0.73 
10-V-00-3-009 Aplysina sp. 0.77 
11-V-00-3-009 Auletta sp. 0.83 
23-XI-96-1-006 Choristida sp. 1.2 




CHAPTER FOUR: STRUCTURE ACTIVITY RELATIONSHIP PROFILE FOR 
PREVIOUSLY IDENTIFIED HIT- NORTOPSENTIN A 
Primary Screening of Nortopsentin A Analogs 
Early screening of the first 336 HBOI purified fractions resulted in a potential hit from 
the genus Spongosorites spp known as Nortopsentin A.  The bis(indoyl)imidazole Nortopsentin 
A (Figure 8). 
 
Figure 7 Nortopsentin A Structure 
 
The antimalarial activity of nortopsentin A had never been shown before.  Nortopsentin 
A was purified and sent to UCF for additional screening.  Nortopsentin A demonstrated effective 
antimalarial activity in both the 3D7 (choloroquine sensitive) and the Dd2 (chloroquine resistant) 
strains.   
The mechanism of action for nortopsentin A was previously studied in our laboratory by 
culturing parasites in nortopsentin A drug treated culture.  In that study nortopsentin A was 
shown to inhibit development beyond the early trophozoite stage which supported the claim of 
previous studies which showed that topsentin compounds can intercalate with DNA and inhibit 
DNA synthesis [52].   
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With this potentially novel mechanism of action among antimalarials, nortopsentin A was 
escalated in lead development.  Recent screening for antiplasmodial and cytotoxicity IC50 show 
an IC50 for Nortopsentin A against Dd2 at 580nM and a cytotoxicity IC50 value of 6µM as shown 
in Figure 9. 
 
A                                                                                B 
 
Figure 8- In-Vitro Antimalarial and Cytotoxic Analysis of Nortopsentin A. 
(A) Determination of the antimalarial activity of nortopsentin A in Dd2 strains of P. falciparum. 
Asynchronous cultures were exposed to different concentrations of inhibitor for 72 hrs. 
(B) Cytotoxicity of nortopsentin A. Varying concentrations of nortopsentin A was incubated 
with NIH 3T3 fibroblast cells for 48 hours to determine the cytotoxicity IC50 value. All data 




Structure Activity Relationship Profiling 
 In order to assist medicinal chemistry in lead optimization, it is important to develop a 
structure activity relationship for any potential lead.  For the compound nortopsentin A, six 
chemical analogs were selected.  These six analogs, along with nortopsentin A, were screened 
against the chloroquine resistant Plasmodium strain Dd2.  Following an IC50 determination, all 
compounds were also screened for cytotoxicity against the NIH 3T3 fibroblast cell line using the 
MTS cell viability assay described in the methods section.  This data was collected and used to 
determine a selectivity index for each compound and is shown in Table 8. 
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Table 9 Bis(indolyl)imidazole Structural Analogs 
 












Nortopsentin A 0.58 6 10
Hamacanthin-A 3.2 30 9.4
Dragmacidin-D 5.2 27 5.2





Deoxytopsentin 8.4 20 2.4
Hamacanthin-B >20 38 <1.9
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CHAPTER FIVE: DISCUSSION 
HBOI Marine Peak Fraction Library 
  Culture screening of over 2,600 marine peak fractions from the Harbor Branch 
Oceanographic Institute against the 3d7 strain of Plasmodium falciparum resulted in 253 
fractions which inhibit at least 70% of parasite growth at 5µg/mL.  This nearly 10% hit rate is 
consistent with typical natural product library screening showing significantly higher hit rate 
percentages as compared to synthetic library screening, as mentioned previously.  From these 
253 compounds we identified 20 species of marine organisms which inhibit Plasmodium 
falciparum growth from which the 35 fractions were selected for further study.  83% of the 35 
fractions were also active in the chloroquine resistant Plasmodium falciparum Dd2 strain. 
Further dereplication led to purified fractions from 6 different species, one of which, 
Spongosorites sp, is the source of the antimalarial near-early lead compound nortopsentin A as 
discussed previously.  Five additional compounds from four chemical classes have also been 
identified from these species and they are shown along with their genus source in table 10.  
Additional structure activity relationship profiling, pharmacodynamics/pharmacokinetic studies 





Table 10-UCF-HBOI novel antimalarial compounds 













Nortopsentin A Structure Activity Relationship 
 The preliminary screening of nortopsentin A showed antimalarial activity in both 
chloroquine sensitive and chloroquine resistant strains.  A novel mechanism of action among 
antimalarial drugs was also demonstrated.  To further escalate nortopsentin A towards lead 
development, a collection of six structural analogs, along with nortopsentin A, was sent from the 
HBOI library for development of a structure activity relationship.   
Of all the compounds tested, nortopsentin A was the most potent and had the greatest 
selectivity.  Addition of a keto group both decreased antiplasmodial activity and selectivity as 
seen in deoxytopsentin.  With respect to all the nitrogenated six member heterocycle rings tested, 
low µM antiplasmodial activity was maintained and selectivity decreased steadily with respect to 
the level of saturation which could be due to subsequent molecular loss of planarity.  The only 
exception to this trend was hamacanthin A.  Interestingly, when the pyrazinone linker attachment 
in hamacanthin A changes to the 5 position the antiplasmodial activity is lost, as seen with 
hamacanthin B.  It seems from this structure activity relationship profile that molecular planarity 
and a maintained distance between the two indole rings is essential for optimal antimalarial 
activity.   
Although nortopsentin A had the best activity and selectivity, further medicinal chemistry 






There is a critical need to find new antimalarial chemical scaffolds.  This screening of 
2,835 marine peak fractions has identified 5 new chemical classes which inhibit Plasmodium 
falciparum at submicromolar levels.  One of these classes, the topsentin class from the 
Sporosorites sp., appears to intercalate parasite DNA and prevent DNA synthesis.  This is a 
novel mechanism of action amongst current antimalarial drugs.  From the structure activity 
relationship profile it is clear that the antimalarial potency of topsentin compounds is dependent 
upon the distance between the two indole rings and the molecular planarity of the compound.   
Future studies will include medicinal chemistry optimization of nortopsentin A to enlarge 
the selectivity index before the compound can be escalated in pre-clinical drug development.  
The mechanism of action and structure activity relationships for each of the four additionally 
identified scaffolds is also necessary.  Furthermore, it is anticipated that dereplication of the 
purified peak fractions from the nine newly identified species with submicrogram/mL IC50, will 
likewise reveal additional novel antimalarial scaffolds which can then be escalated along the 
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